204 related articles for article (PubMed ID: 27068437)
1. Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.
Ruan J; Martin P
Curr Hematol Malig Rep; 2016 Jun; 11(3):234-40. PubMed ID: 27068437
[TBL] [Abstract][Full Text] [Related]
2. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
[TBL] [Abstract][Full Text] [Related]
3. Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11.
Croci GA; Hoster E; Beà S; Clot G; Enjuanes A; Scott DW; Cabeçadas J; Veloza L; Campo E; Clasen-Linde E; Goswami RS; Helgeland L; Pileri S; Rymkiewicz G; Reinke S; Dreyling M; Klapper W
Virchows Arch; 2020 Aug; 477(2):259-267. PubMed ID: 31975037
[TBL] [Abstract][Full Text] [Related]
4. Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Isaac KM; Portell CA; Williams ME
Curr Oncol Rep; 2021 Jul; 23(9):102. PubMed ID: 34269910
[TBL] [Abstract][Full Text] [Related]
5. [Right cervical lymph node enlargement].
Xie JL; Zhou XG; Wang ZQ
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):273-4. PubMed ID: 23928539
[No Abstract] [Full Text] [Related]
6. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
7. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
8. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
9. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.
Nygren L; Baumgartner Wennerholm S; Klimkowska M; Christensson B; Kimby E; Sander B
Blood; 2012 May; 119(18):4215-23. PubMed ID: 22431568
[TBL] [Abstract][Full Text] [Related]
11. Transplantation for mantle cell lymphoma: is it the right thing to do?
Williams ME
Hematology Am Soc Hematol Educ Program; 2013; 2013():568-74. PubMed ID: 24319233
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma in the ocular adnexal region.
Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
[TBL] [Abstract][Full Text] [Related]
13. SOX11, a key oncogenic factor in mantle cell lymphoma.
Beekman R; Amador V; Campo E
Curr Opin Hematol; 2018 Jul; 25(4):299-306. PubMed ID: 29738333
[TBL] [Abstract][Full Text] [Related]
14. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
Silkenstedt E; Linton K; Dreyling M
Br J Haematol; 2021 Oct; 195(2):162-173. PubMed ID: 33783838
[TBL] [Abstract][Full Text] [Related]
16. How I manage mantle cell lymphoma: indolent versus aggressive disease.
Wilson MR; Barrett A; Cheah CY; Eyre TA
Br J Haematol; 2023 Apr; 201(2):185-198. PubMed ID: 36807902
[TBL] [Abstract][Full Text] [Related]
17. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
18. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
[TBL] [Abstract][Full Text] [Related]
19. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Klener P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
